Erratum to: circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.

Kaiyun Qin, Fenghua Zhang, Hongxia Wang, Na Wang, Hongbing Qiu, Xinzhuan Jia, Shan Gong, Zhengmao Zhang

Abstract readPublished Erratum

In one paragraph

Article in BMB reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

Erratum for
circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis.2023

5 · Who and what money

Authors and funding

8 authors.

Kaiyun QinDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011; Department of Gynecology, Hebei General Hospital, Hebei Shijiazhuang 050057, China.

Fenghua ZhangDepartment of Breast & Thyroid Surgery, Hebei General Hospital, Hebei Shijiazhuang 050057, China.

Hongxia WangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China.

Na WangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China.

Hongbing QiuDepartment of Gynecology, Hebei Xingtai People's Hospital, Hebei Shijiazhuang 054001, China.

Xinzhuan JiaDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011; Department of Reproductive Medicine, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China.

Shan GongDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China.

Zhengmao ZhangDepartment of Gynecology, Fourth Hospital of Hebei Medical University, Hebei Shijiazhuang 050011, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

[Erratum to: BMB Reports 2023; 56(3): 184-189, PMID: 36617466, PMCID: PMC10068343] The BMB Reports would like to correct in BMB Rep. 56(3): 184-189, titled "circRNA circSnx12 confers Cisplatin chemoresistance to ovarian cancer by inhibiting ferroptosis through a miR-194-5p/SLC7A11 axis". The original version of this article unfortunately contained image error in the Fig. 3. This article has been updated to correct an error in the image in Fig. 3D. The author apologizes for any inconvenience or confusion this error may cause. Author information has been modified in the original PDF version.

Identifiers

PMID38416113

PMCPMC10910093

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.